Effect of budesonide oral suspension on dysphagia and esophageal inflammation in eosinophilic esophagitis: a systematic review and meta-analysis - Report - MDSpire

Effect of budesonide oral suspension on dysphagia and esophageal inflammation in eosinophilic esophagitis: a systematic review and meta-analysis

  • By

  • Darío S. López Delgado

  • Carlos A. Narváez

  • Gloria L. Chapues-Andrade

  • María A. Matus-Hernández

  • Veraliz González-Hidalgo

  • Gerson Diaz-Gonzales

  • Oriana Rivera-Lozada

  • Joshuan J. Barboza

  • July 8, 2026

  • 0 min

Share

Clinical Report: Impact of Budesonide Oral Suspension on Eosinophilic Esophagitis

Overview

This systematic review and meta-analysis evaluated the efficacy and safety of budesonide oral suspension (BOS) in treating eosinophilic esophagitis (EoE).

Background

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated condition characterized by eosinophilic inflammation of the esophagus, leading to dysphagia and food impaction. Effective management is crucial as EoE can significantly impact quality of life. Budesonide oral suspension (BOS) is a topical corticosteroid designed to enhance mucosal contact and reduce inflammation in EoE patients.

Data Highlights

OutcomeMean Difference (MD)95% Confidence Interval (CI)
Histologic outcomes-54.62 eos/hpf-68.19 to -41.05
Endoscopic severity-1.68-3.09 to -0.26
Patient-reported symptom severity-3.29 points-6.17 to -0.40

Key Findings

  • BOS significantly improved histologic outcomes compared to placebo (MD = -54.62 eos/hpf).
  • Endoscopic severity showed significant improvement (MD = -1.68).
  • Patient-reported symptom severity improved with a pooled MD of -3.29 points.
  • Treatment-emergent adverse events were similar between BOS and placebo groups.
  • Serious adverse events were rare in both treatment groups.

Clinical Implications

BOS is effective in reducing esophageal inflammation and alleviating dysphagia in patients with EoE.

Conclusion

BOS demonstrates significant efficacy in treating eosinophilic esophagitis.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Impact of Budesonide Oral Suspension on Esophageal Inflammation and Swallowing Difficulties in Eosinophilic Esophagitis
  2. the new gastroenterologist — Eosinophilic esophagitis: A year in review
  3. The New Gastroenterologist — Extended Treatment for Eosinophilic Esophagitis Reduces Relapse Risk Without Increased Complications
  4. Frontiers in Pediatrics — Maintenance oral viscous budesonide reduces dilation recurrence after esophageal atresia repair: a prospective clinical study
  5. The New Gastroenterologist — Long-Term Findings Endorse Reduced-Dose Maintenance Therapy for Eosinophilic Esophagitis
  6. Eosinophilic esophagitis: A year in review
  7. Extended Treatment for Eosinophilic Esophagitis Reduces Relapse Risk Without Increased Complications
  8. Maintenance oral viscous budesonide reduces dilation recurrence after esophageal atresia repair: a prospective clinical study
  9. Long-Term Findings Endorse Reduced-Dose Maintenance Therapy for Eosinophilic Esophagitis
  10. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis
  11. Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results From a Phase 3 Trial - Clinical Gastroenterology and Hepatology
  12. Budesonide Oral Suspension (EOHILIA) in Eosinophilic Esophagitis

Original Source(s)

Effect of budesonide oral suspension on dysphagia and esophageal inflammation in eosinophilic esophagitis: a systematic review and meta-analysis

  • by Darío S. López Delgado, Carlos A. Narváez, Gloria L. Chapues-Andrade, María A. Matus-Hernández, Veraliz González-Hidalgo, Gerson Diaz-Gonzales, Oriana Rivera-Lozada, Joshuan J. Barboza

  • July 8, 2026

Related Content

Investigation of cerebral cortical morphological similarity and network topological abnormalities in hepatic encephalopathy utilizing a morphometric inverse divergence network framework

Post-endoscopy gastric cancer in Latin America: a multicentre cohort study from Colombia

PON1 haplotypes show genotype-dependent associations with dysglycemia and metabolic liver risk beyond paraoxonase activity